Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non–Small-Cell Lung Cancer
Authors:
- 1 November 2013
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (6) , 644-650
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center ExperiencePLOS ONE, 2012
- Socioeconomic Disparities in Lung Cancer Treatment and Outcomes Persist Within a Single Academic Medical CenterClinical Lung Cancer, 2012
- Predictive Ability of Charlson Comorbidity Index on Outcomes From Lung CancerAmerican Journal of Clinical Oncology, 2011
- Disparities Between Blacks and Whites in Tobacco and Lung Cancer TreatmentThe Oncologist, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance TherapyJournal of Thoracic Oncology, 2011
- Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology GroupJNCI: Journal of the National Cancer Institute, 2009
- Comorbidities and Charlson score in resected stage I nonsmall cell lung cancerEuropean Respiratory Journal, 2005
- Racial Differences in the Treatment of Early-Stage Lung CancerNew England Journal of Medicine, 1999
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987